Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sigyn Therapeutics Inc (QB) | SIGY | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.00 | 15:20:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.00 | 5.00 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.052 - 6.34 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 5.00 | USD |
Sigyn Therapeutics Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 221.12M | 44.22M | 8.63M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sigyn Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/31/2024 | 15:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/30/2024 | 15:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/11/2024 | 14:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/08/2024 | 13:34 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/12/2023 | 13:48 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/26/2023 | 14:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/04/2023 | 16:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/19/2023 | 14:56 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/14/2023 | 14:35 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/07/2023 | 10:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/17/2023 | 06:15 | InvestorsHub NewsWire | Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SIGY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.25 | 5.25 | 5.00 | 5.09 | 413 | -0.25 | -4.76% |
| 1 Month | 6.25 | 6.34 | 5.00 | 5.55 | 285 | -1.25 | -20.00% |
| 3 Months | 5.00 | 6.34 | 4.50 | 5.34 | 335 | 0.00 | 0.00% |
| 6 Months | 0.141 | 6.34 | 0.09 | 0.2655004 | 5,932 | 4.86 | 3,446.10% |
| 1 Year | 0.11514 | 6.34 | 0.052 | 0.1834911 | 9,634 | 4.88 | 4,242.54% |
| 3 Years | 1.66 | 6.34 | 0.052 | 0.3315261 | 7,872 | 3.34 | 201.20% |
| 5 Years | 1.8501 | 6.34 | 0.052 | 0.5328645 | 6,244 | 3.15 | 170.26% |
Sigyn Therapeutics (QB) Description
| Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy, the Companys lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy include chronic inflammation and endotoxemia in end-stage renal disease patients, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the delivery of FDA approved chemotherapeutic agents and ChemoPure to reduce chemotherapy toxicity. |
